RCUS Q1 2022 Earnings — Arcus Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

RCUSArcus Biosciences, Inc.

$2B

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$18M+90.3% YoY

Gross Profit

$18M100.0% margin

Operating Income

-$67M-372.2% margin

Net Income

-$68M-377.8% margin

EPS (Diluted)

$-0.96

QoQ Revenue Growth

-94.9%

Cash Flow

Operating Cash Flow

$654M

Free Cash Flow

$651M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$747M

Stockholders' Equity

$797M

Cash & Equivalents

$549M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$18M	$9M	+90.3%
Gross Profit	$18M	$9M	+90.3%
Operating Income	-$67M	-$73M	+7.9%
Net Income	-$68M	-$73M	+6.3%

Revenue Segments

Gilead Access Rights

$8M46%

License and Development Services for All Gilead Programs

$8M44%

Taiho Access Rights

$2M10%